SMARCA1 and leukemia: Considering that activation of endogenous NF-κB activity has been observed in many epithelial tumors cells as well as melanomas and various leukemias and myelomas1,2,4,5, we believe CT1 would be effective to wide variety of tumors competent for the functional SWI/SNF complex.